RNTX
Rein Therapeutics
$0.78
−$0.01 (−1.14%)Jul 27, 2026
Key metrics
The numbers that frame RNTX today
- Market cap
- $66.89M
- P/E (TTM)
- -1.3
- EV / FCF
- -4.1
- ROIC
- 976.8%
- Div yield
- 0%
- Debt / equity
- 0.4
- 52wk Low
- $0.76
- 52wk High
- $2.18
Growth
Revenue and earnings trend for RNTX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RNTX
Is Rein Therapeutics a good buy?
No. Rein Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Rein Therapeutics is selling at a very high price.
What is the market capitalization of RNTX?
Rein Therapeutics's market capitalization is $66.89M.
What is the P/E ratio for RNTX stock?
Rein Therapeutics's current P/E ratio is -1.3.
What is the 52-week high for RNTX stock?
The 52-week high for Rein Therapeutics is $2.18. The current close of $0.78 is 64.1% below that high.
What is the 52-week low for RNTX stock?
The 52-week low for Rein Therapeutics is $0.76. The current close of $0.78 is 3.2% above that low.
Does RNTX stock pay dividends?
Rein Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for RNTX?
Rein Therapeutics's Debt / Equity ratio is 0.43.